Soligenix, Inc. (SNGX)

Oncology Corporate Profile

Stock Performance

2.4500
0.0000

HQ Location

29 Emmons Drive Suite C-10
Princeton, NJ 08540

Company Description

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Website: http://soligenix.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SGX301photodynamic therapyCutaneous T-Cell LymphomaIII
SGX942innate defense regulatorHead & Neck cancerII

View additional information on product candidates here »

Pipeline image

Source


http://soligenix.com

Recent News Headlines

Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results

3/27/2017 11:03 am

[PR Newswire] - PRINCETON, N.J., March 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2016. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are extremely pleased with the positive results from the Phase 2 study of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer.

Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference

3/15/2017 10:03 am

[PR Newswire] - PRINCETON, N.J., March 15, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix will present preclinical and clinical results on the use of dusquetide (SGX94) in the treatment of emerging and antibiotic resistant infectious diseases at Superbugs & Superdrugs – A Focus on Antibacterials. The conference is being held in London March 20-21, 2017. Innate Defense Regulators: Agnostic Therapy For Antibiotic Resistant Disease – "Supercharging existing and new antibiotic therapies," presented by Dr. Oreola Donini, Chief Scientific Officer of Soligenix, on March 20, 2017 at 1:20 pm local time. Conference details are available here.

Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting

3/10/2017 11:03 am

[PR Newswire] - PRINCETON, N.J., March 10, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present results from its ricin toxin vaccine (RiVax™) development program at the Society of Toxicology 56th Annual Meeting. Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to Support Vaccine Development presented by Dr. Gensheng Wang, Lovelace Respiratory Research Institute and Dr. Thomas Measey, Soligenix Inc. RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin.

Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis

2/22/2017 11:00 am

[PR Newswire] - PRINCETON, N.J., Feb. 22, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

2/2/2017 11:00 am

[PR Newswire] - PRINCETON, N.J., Feb. 2, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today SGX301 (synthetic hypericin) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of cutaneous T-cell lymphoma (CTCL). The PIM designation is the first step towards inclusion in the Early Access to Medicines Scheme (EAMS). Launched in April 2014, EAMS offers severely ill patients with life-threatening and seriously debilitating conditions the lifeline of trying ground-breaking new medicines much earlier than they would normally be accessible.

Soligenix to Present at 9th Annual Biotech Showcase Conference

1/6/2017 11:00 am

[PR Newswire] - PRINCETON, N.J., Jan. 6, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present a company overview at the 9th Annual Biotech Showcase Conference on Wednesday, January 11, 2017 at 9:30 a.m. PST. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients

1/5/2017 10:05 pm

[at noodls] - Follows UK Health Ministry's Granting SGX942 Promising Innovative Medicine Designation in the Treatment of Oral Mucositis Princeton, NJ, January 5, 2017 - Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical ...

Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients

1/5/2017 11:00 am

[PR Newswire] - PRINCETON, N.J., Jan. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there ...

Soligenix Announces Extension of Development Agreement with Emergent BioSolutions

1/3/2017 09:00 pm

[at noodls] - Supported with NIAID Contract Funding of up to $24.7 million Princeton, NJ - January 3, 2017 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused ...

Soligenix Announces Extension of Development Agreement with Emergent BioSolutions

1/3/2017 12:00 pm

[PR Newswire] - PRINCETON, N.J., Jan. 3, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

Soligenix Advances Collaboration with IDT Biologika

12/20/2016 08:00 pm

[at noodls] - Supported with NIAID Contract Funding of up to $24.7 million Princeton, NJ - December 20, 2016 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused ...

Soligenix Advances Collaboration with IDT Biologika

12/20/2016 12:00 pm

[PR Newswire] - PRINCETON, N.J., Dec. 20, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has extended its collaboration with IDT Biologika (hereafter referred to as IDT) for the manufacture of RiVax™, the Company's proprietary heat-stable ricin toxin vaccine. Under the terms of the collaboration, Soligenix will scale-up the formulation/filling processes and continue development and validation of analytical methods established at IDT to advance the program towards a commercially viable scalable technology for the RiVax™ vaccine product compliant with current Good Manufacturing Practices (cGMPs).

Soligenix Announces Closing of Public Offering

12/16/2016 10:04 pm

[at noodls] - Princeton, NJ, December 16, 2016 - Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Soligenix Announces Closing of Public Offering

12/16/2016 09:02 pm

[PR Newswire] - PRINCETON, N.J., Dec. 16, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16. Gross proceeds to Soligenix, Inc. from this offering are approximately $5,277,270 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Soligenix, Inc. A copy of the final prospectus, dated December 12, 2016, relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

SOLIGENIX, INC. Financials

12/16/2016 06:00 pm

Soligenix, Inc. Prices $5,277,000 Public Offering and Completes Listing on Nasdaq

12/13/2016 11:00 am

[PR Newswire] - PRINCETON, N.J., Dec. 13, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the pricing of an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Soligenix, Inc. from this offering are expected to be approximately $5,277,200, before deducting underwriting discounts and commissions and other estimated offering expenses.